SANTEN AND SINGAPORE EYE RESEARCH INSTITUTE (SERI) ANNOUNCE AN EXPANDED RELATIONSHIP INCLUDING THE CREATION OF A NEW JOINT LABORATORY TO DEVELOP NOVEL OPHTHALMIC THERAPEUTICS, DIAGNOSTICS AND DEVICES

March 2, 2017, Singapore and Osaka, Japan – Santen Pharmaceutical Co., Ltd. (Osaka, Japan, “Santen”) and the Singapore Eye Research Institute (Singapore, "SERI") announced today they have launched a strategic, five-year collaboration designed to develop new technologies in ophthalmology by bringing together the two parties' capabilities in ophthalmic R&D, with a special focus on diseases prevalent in Asia. The parties aim to invest a total of SGD37million over the next 5 years in a Santen-SERI joint laboratory by bringing together support from Santen and the Singapore government.

Leveraging on the two parties’ existing collaboration, key programmes already underway will be expanded and extended to include additional therapeutic domains and technologies. This research focus brings together Santen’s asset portfolio and longstanding drug development program, and SERI’s novel technologies and translational research capabilities. As part of this expansion a Santen-SERI joint lab will be set up at the Academia building on the SingHealth campus at Outram Park, which will include scientists from both parties working side-by-side on new product development. Santen’s team will include a substantial number of local hires who will work under experienced scientists from Japan and elsewhere. The team will work with scientists and clinicians across the research community.

These co-development R&D activities will focus on a number of key ophthalmic domains in which SERI and Santen have deep experience and can achieve substantial synergy in working together, such as glaucoma, diabetic retinopathy, ocular infections and myopia, with the goal of establishing a robust pipeline of ophthalmic products which will benefit patients in Singapore, Asia and globally.

“We are very pleased to extend and expand our partnership with SERI. The last two years have seen good progress and a number of successes on several of our combined R&D projects, which we are confident will translate into pipeline products.” said Naveed Shams, Senior Corporate Officer, Chief Scientific Officer and Head of Global R&D at Santen. “This next expanded phase of our collaboration will allow us to bring candidate compounds to a clinical development stage and to commence work in new domains. Partnerships such as ours with SERI are an important component in our R&D activities in helping us conduct broader, multidisciplinary work, thereby enabling us to better develop innovative therapeutics and other technologies to answer current and future unmet medical needs in ophthalmology.”

“We’re very excited to be expanding our collaboration with Santen following a productive two years, during which we’ve shown that bringing together the experience and capabilities of both parties results in efficient development of new therapeutics and delivery systems that hold great promise for patients in Singapore and around the world” said Prof. Tin Aung, Executive Director of SERI. “SERI will leverage its substantial experience in translational ophthalmic research and the leading position we’ve achieved in several ophthalmic fields towards expanding the work we’re doing with Santen. Over the past two years we’ve seen
tremendous progress being made and we’re confident this can be carried forward to great success for both sides.”

ABOUT SANTEN PHARMACEUTICAL CO., LTD

As a specialty company dedicated to the ophthalmic field, Santen carries out research, development, sales, and marketing of pharmaceuticals. Santen is the market leader in Japan for prescription ophthalmic pharmaceuticals and sells products in over 50 countries. As a leading company in the field of ophthalmology, Santen aims to contribute to society by supplying valuable products and services to satisfy unmet medical needs.

For more details, please see Santen’s website (www.santen.com).

Please be notified that the collaboration mentioned above does not include financial capital collaboration between the two parties. Please also be notified that Santen does not expect to make any revision in previously issued financial forecasts in relation to this collaboration arrangement.

ABOUT THE SINGAPORE EYE RESEARCH INSTITUTE (SERI)

Established in 1997, SERI is Singapore’s national research institute for ophthalmic and vision research. SERI’s mission is to conduct high impact eye research with the aim to prevent blindness, low vision and major eye diseases common to Singaporeans and Asians. SERI has grown from a founding team of five in 1997 to a faculty of 223, encompassing clinician scientists, scientists, research fellows, PhD students and support staff. This makes SERI one of the largest research institutes in Singapore and the largest eye research institute in Asia-Pacific. In addition, SERI has over 100 adjunct faculties from various eye departments, biomedical institutes and tertiary centres in Singapore. SERI has amassed an impressive array of more than 2700 publications, scientific papers as of December 2016, and has secured more than 260 external peer-reviewed competitive grants worth $227 million. To date, as of December 2016, SERI’s faculty has been awarded more than 400 national and international prizes and filed more than 100 patents. Serving as the research institute of the Singapore National Eye Centre and affiliated to the Duke-NUS Graduate Medical School, SERI undertakes vision research in collaboration with local clinical ophthalmic centres and biomedical research institutions, as well as major eye centres and research institutes throughout the world.

For more information about SERI, visit http://www.seri.com.sg.

Santen Forward-looking Statements

Information provided in this press release contains so-called “Forward-looking Statements”. The realizations of these forecasts are subject to risk and uncertainty from various sources. Therefore, please note that the actual results may differ significantly from the forecasts. Business performance and financial condition are subject to the effects of change in regulations made by the governments of Japan and other nations concerning medical insurance, drug pricing and other systems, and to fluctuations in market variables such as interest rates and foreign exchange rates.
Santen contact
Christopher Hohman
E-mail: ir@santen.co.jp
Tel: +81-6-4802-9360

SERI media contact
Ravi Chandran
Email: ravi.chandran@snec.com.sg
Tel: +65-81218569